HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
Portfolio Pulse from
The FDA announced that the shortage of Ozempic and Wegovy, drugs produced by Novo Nordisk, is over. This news could impact the stock prices of Novo Nordisk and Eli Lilly, both involved in the GLP-1 market.
February 24, 2025 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
With Novo Nordisk resolving its supply issues, Eli Lilly may face increased competition in the GLP-1 market, potentially impacting its market share.
Novo Nordisk's resolution of its supply issues may lead to increased competition for Eli Lilly in the GLP-1 market, but the direct impact on Eli Lilly's stock is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
The FDA's announcement that the Ozempic and Wegovy shortage is over is positive for Novo Nordisk, potentially boosting its stock price as supply issues are resolved.
The resolution of the Ozempic and Wegovy shortage means Novo Nordisk can meet demand, likely leading to increased sales and a positive impact on stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100